Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

New England Journal of Medicine

Volumn 372, Issue 7, 2015, Pages 621-630

  Schlumberger, Martin ^a   Tahara, Makoto ^b   Wirth, Lori J ^d   Robinson, Bruce ^e   Brose, Marcia S ^f   Elisei, Rossella ^g   Habra, Mouhammed Amir ^h   Newbold, Kate ⁱ   Shah, Manisha H ^k   Hoff, Ana O ^l   Gianoukakis, Andrew G ^m   Kiyota, Naomi ^c   Taylor, Matthew H ⁿ   Kim, Sung Bae ^o   Krzyzanowska, Monika K ^p   Dutcus, Corina E ^q   De Las Heras, Begoña ^j   Zhu, Junming ^q   Sherman, Steven I ^h  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^j EISAI CO LTD   (Japan)

^k OHIO STATE UNIVERSITY   (United States)

^l UNIVERSITY OF SÃO PAULO   (Brazil)

^m HARBOR UCLA MEDICAL CENTER   (United States)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o University of Ulsan College of Medicine   (South Korea)

^p PRINCESS MARGARET HOSPITAL   (Canada)

^q EISAI INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LENVATINIB; PLACEBO; RADIOACTIVE IODINE; 4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; HYPOCALCEMIA; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; THYROID NEOPLASMS;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; THYROID NEOPLASMS;

EID: 84922742421     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1406470     Document Type: Article

References (32)

1. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.
2. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endo-crinol Metab 2006;91:2892-9.
3. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocri-nol 2014;2:356-8.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9: 669-76.
5. Yu XM, Lo CY, Lam AK, Leung P, Luk JM. Serum vascular endothelial growth factor C correlates with lymph node me-tastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008;247:483-9.
6. Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol 2011;37:93-9.
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
8. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5.
9. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003;88:2341-7.
10. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146: 1145-53.
11. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002; 13:3-16.
12. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-93.
13. He G, Zhao B, Zhang X, Gong R. Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett 2014;7:439-43.
14. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009;94: 4735-41.
15. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23:1191-200.
16. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyro-sine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109.
17. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384: 319-28.
18. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8.
19. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, ra-dioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11: 962-72.
20. Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharma-cokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014;120: 2694-703.
21. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioio-dine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.
22. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or meta-static differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905.
23. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-71.
24. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-65.
25. Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radio-iodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29: Suppl:5503. abstract.
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
27. National Cancer Institute. Protocol development: Cancer Therapy Evaluation Program, 2013 (http://ctep.cancer.gov/protocoldevelopment/electronic- applications/ctc.htm#ctc-40).
28. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2007 (http://www.fda.gov/downloads/Drugs/../Guidances/ucm071590.pdf).
29. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 1991;20:2609-31.
30. Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and pro-teinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharma-cokinet Pharmacodyn 2010;37:347-63.
31. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endo-thelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
32. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for meta-static thyroid cancer. J Thyroid Res 2011; 2011:985780.